Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 14Radiotherapy 14Carboplatin 7Irinotecan 6Everolimus 5Filgrastim 4Carmustine 4Surgical Procedures, Operative 3Radiation 3Paclitaxel 3Ifosfamide 3selpercatinib 2pembrolizumab 2Trastuzumab 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Methotrexate 2Imatinib Mesylate 2IL13-PE38 2Dasatinib 2Chemotherapy, Adjuvant 2Bevacizumab 2vitespin 1veliparib 1vatalanib 1transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38) 1tipifarnib 1terameprocol 1temsirolimus 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Central Nervous System Neoplasms × Maintenance × Clear all
NCT03690869 2025-04-08

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Regeneron Pharmaceuticals

Phase 1/2 Terminated
57 enrolled 31 charts
CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Recurrence, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡